GoKawiilnChroma Bio's epigenetic therapy silences hepatitis B virus in animal trials, now testing in humans
Researchers at nChroma Bio and Milan-based institutes developed a therapy that attaches chemical tags to the hepatitis B virus genome, silencing its genes without cutting DNA. Tests in human liver cells and mice showed the approach effectively blocked viral particle production, and monkey trials revealed only mild, short-lived side effects after a single dose. A human clinical trial has since begun in Hong Kong and New Zealand, with the first patient dosed in January.